 |
Cardiometabolic Risk in the Spotlight: Which Therapies Should Take Center Stage? CME Richard W Nesto, MD, Co-chair; Sidney C Smith, Jr, MD, Co-chair; Charles B Nemeroff, MD, PhD; Uberto Pagotto, MD, PhD; Jorge Plutzky, MD; Daniel J Rader, MD Author Information and Disclosures Release Date: January 28, 2008; Valid for credit through January 28, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | The content of this CME activity, "Cardiometabolic Risk in the Spotlight: Which Therapies Should Take Center Stage?", was developed by the faculty.
To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 INNOVIA Education Institute, LLC. |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Understand the interrelated role of cardiometabolic risk factors-including obesity, dyslipidemia, and diabetes-in the global pandemic of cardiovascular disease
(CVD);
- Recognize the relationship between obesity and depression and its clinical implications;
- Apply evidence-based treatment guidelines for the management of cardiometabolic risk factors to patient cases;
- Analyze the mechanism of action and evidence for the effectiveness of cannabinoid receptor type 1 (CB1) blockade in CVD;
- Evaluate real-world clinical practice issues, including target patient
populations, choice and combination of interventions, treatment side effects, patient adherence issues, and barriers to treatment.
Author Disclosures Sidney C. Smith, Jr., MD
Disclosure: Dr. Smith has disclosed that he has received honoraria for speaking and served as a
consultant for Bayer, Merck, Pfizer, and sanofi-aventis/Bristol-Myers Squibb. He has also served as a consultant for AstraZeneca. Daniel J. Rader, MD
Disclosure: Dr. Rader has disclosed that he has no relevant financial relationships. Richard W. Nesto, MD
Disclosure: Dr. Nesto has disclosed that he has served on the speakers' bureau and advisory board
for sanofi-aventis. Jorge Plutzky, MD
Disclosure: Dr. Plutzky has disclosed that he has served as a consultant for GlaxoSmithKline, Novo Nordisk, ONO Pharmaceuticals, and sanofi-aventis. He has also served as a consultant on a speakers' bureau for Takeda. Charles B. Nemeroff, MD, PhD
Disclosure: Dr. Nemeroff has disclosed that he has consulted for,
served on the speakers' bureau and/or board of directors of, been a grant recipient of, and/or owned equity in one or more of the following: Abbott Laboratories, Acadia Pharmaceuticals, American Foundation for Suicide Prevention (AFSP), American Psychiatric Institute for Research and Education (APIRE), AstraZeneca, BMC-JR LLC, Bristol-Myers Squibb, CeNeRx, Corcept, Cypress Biosciences, Cyberonics, Eli Lilly, Entrepreneur's Fund, Forest Laboratories, George West Mental
Health Foundation, GlaxoSmithKline, i3 DLN, Janssen Pharmaceutica, Lundbeck, National Alliance for Research on Schizophrenia and Depression (NARSAD), Neuronetics, National Institute of Mental Health (NIMH), National Foundation for Mental Health (NFMH), NOVADel Pharma, Otsuka, Pfizer Pharmaceuticals, Quintiles, Reevax, UCB Pharma, and Wyeth-Ayerst.
Dr. Nemeroff serves on the scientific advisory board for AstraZeneca, Johnson & Johnson, Pharma Neuroboost, Forest
Laboratories, Quintiles, and NARSAD. He is a grant recipient from National Institutes of Health (NIH), NARSAD, and AFSP. He serves on the board of directors of AFSP, APIRE, NOVADel Pharmaceuticals, and the George West Mental Health Foundation. He owns equity in CeNeRx and Reevax. He owns stock or stock options in Corcept and NOVADel. Uberto Pagotto, MD, PhD
Disclosure: Dr. Pagotto has disclosed that he has served as
consultant to and received honoraria from sanofi-aventis, and served as a consultant for Merck. The peer reviewer for this activity, Ryan Nguyen, PharmD, has disclosed that he has no relevant financial relationships. The content collaborators at INNOVIA Education Institute have disclosed that they have no relevant financial relationships.
|
 |
INNOVIA Education Institute, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
INNOVIA Education Institute designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
